Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-08-03 Earnings Release
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin: strong revenues growth in the First Half of 2022 - full Year 2022 Guidance on both Revenues and Profitability revised upwards
Earnings Release Classification · 100% confidence The document is a press release from DiaSorin announcing their H1 2022 financial results. It contains key financial highlights, revenue breakdowns, EBITDA, and revised guidance. While it references the 'Half-Year Financial Report', the document itself is the initial earnings announcement (Earnings Release) providing highlights and commentary, not the full statutory interim report. Therefore, it is classified as an Earnings Release. H1 2022
2022-08-03 English
DiaSorin: fatturato in forte crescita nel 1° semestre 2022 - guidance per l’esercizio 2022 su ricavi e marginalità rivista al rialzo
Earnings Release Classification · 95% confidence The document is a press release from DiaSorin S.p.A. announcing its financial results for the first half of 2022. It contains key financial highlights, tables of results, and guidance updates. While it mentions the approval of the 'Relazione Finanziaria Semestrale' (Interim Financial Report), the document itself is the initial announcement of these results (Earnings Release) rather than the full statutory report. It provides the summary data and highlights typical of an earnings release. H1 2022
2022-08-03 Italian
Report on the treasury shares buy-back plan of DiaSorin S.p.A. - Period 18/07/2022- 22/07/2022
Transaction in Own Shares Classification · 98% confidence The document is titled 'WEEKLY REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.' and details the number of shares purchased, the consideration, and the resulting treasury share holding over a specific weekly period (July 18, 2022 - July 22, 2022). This content directly relates to the company managing its own stock, which falls under the category of 'Transaction in Own Shares'. The code for this is POS.
2022-07-25 English
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 18/07/2022 -22/07/2022
Transaction in Own Shares Classification · 98% confidence The document is titled "INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A." (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.). It details the number of own shares purchased during the period 18/07/2022 - 22/07/2022. This activity directly relates to the company buying back or selling its own shares, which corresponds precisely to the definition of 'Transaction in Own Shares' (POS). Although it is a report, it is a specific regulatory disclosure about share transactions, not a general capital change (SHA) or a general regulatory filing (RNS).
2022-07-25 Italian
Report on the treasury shares buy-back plan of DiaSorin S.p.A. - Period 14/06/2022- 17/06/2022
Transaction in Own Shares Classification · 98% confidence The document is titled 'WEEKLY REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.' and details the number of shares purchased, the average price, and the total consideration for the period June 14, 2022, to June 17, 2022. This content specifically relates to the company acquiring its own shares (share repurchase). This aligns directly with the definition for 'Transaction in Own Shares' (Code: POS). Although it is a 'Weekly Report', the core subject matter is the transaction itself, not just an announcement of a report's publication (which would be RPA/RNS). Since the document provides the detailed transaction data, POS is the most accurate classification.
2022-06-20 English
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 14/06/2022 - 17/06/2022
Transaction in Own Shares Classification · 99% confidence The document is an 'INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A.' (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.). It details the number of own shares purchased during a specific period (June 14 to June 17, 2022) and provides a detailed transaction log. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type code is POS.
2022-06-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.